Nyxoah Initiates Succession of Olivier Taelman to Accelerate in the United States
Nyxoah announced on Thursday the launch of a succession process for its CEO position. Olivier Taelman, who has led the company for seven years, is stepping down to make way for an American CEO to accelerate the commercialization of the Genio system in the U.S. market.
Seven Years of Successful Transformation
Olivier Taelman is stepping down as CEO after transitioning Nyxoah from a preclinical stage to a global commercial platform. Under his leadership, the company achieved CE marking in Europe in 2019 and FDA approval in August 2025 for the Genio system, a wireless and battery-free hypoglossal neurostimulation treatment for obstructive sleep apnea. Nyxoah also completed two initial public offerings: on Euronext Brussels in September 2020 and on Nasdaq in July 2021. Taelman will continue to lead the company's daily operations during the transition period to ensure a successful handover and transition to the new CEO.
Commercial Acceleration in the United States
The board of directors has formally initiated a search to identify a new CEO based in the United States. This transition is in response to the company's desire to accelerate its commercial traction in the American market, a critical market for Nyxoah's future growth. Chairman Robert Taub emphasized that the combination of enhanced financial resources, accelerating commercial dynamics in the U.S., and a leadership structure oriented towards the United States would position Nyxoah for its next growth phase in the rapidly expanding obstructive sleep apnea market.
